Skip to content
2000
Volume 25, Issue 1
  • ISSN: 1871-5273
  • E-ISSN: 1996-3181

Abstract

The normal cellular prion protein (PrPC) can misfold into an infectious and pathogenic form (PrPSc) to produce prion diseases, also known as transmissible spongiform encephalopathies (TSEs), which are rare and deadly neurodegenerative conditions. The conversion of PrPC to PrP, which builds up as toxic aggregates in the central nervous system, is caused by sporadic, inherited, or acquired pathways. PrPSc-induced proteostasis failure, oxidative stress, neuronal toxicity, and progressive neurodegeneration are characteristics of pathogenesis. Due to their overlap with other neurodegenerative illnesses, prion diseases are still difficult to diagnose, even with breakthroughs in our knowledge of the molecular causes. Cerebrospinal fluid biomarkers, neuroimaging, EEG, and genetic testing are utilized in the diagnostic process. Methods like real-time quaking-induced conversion (RT-QuIC) provide high sensitivity. As there are currently no cures, the main goals of management are palliative care and symptom alleviation. Research is currently being conducted on experimental strategies that target PrP misfolding. These strategies include autophagy enhancers, monoclonal antibodies, antisense oligonucleotides, and small compounds. Artificial intelligence (AI) shows revolutionary promise by enhancing early diagnosis through biomarker analysis, neuroimaging interpretation, and EEG pattern identification. AI also improves clinical trial design, identifies tailored treatment approaches, and accelerates drug discovery. Furthermore, advancements in AI-based bioinformatics technologies have led to a better understanding of prion biology and strain diversity. The future holds promise for utilising cutting-edge treatment techniques, such as CRISPR and gene therapy, for targeted interventions, as well as combining AI with multimodal data to enhance diagnostic capabilities. There is optimism that the burden of prion disorders can be reduced, and the treatment of neurodegenerative illnesses can be improved through the integration of molecular research, novel treatments, and AI technology.

© 2026 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cnsnddt/10.2174/0118715273381241250620114740
2026-07-08
2026-03-04

  • From This Site

    /content/journals/cnsnddt/10.2174/0118715273381241250620114740
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. LampteyR.N.L. ChaulagainB. TrivediR. GothwalA. LayekB. SinghJ. A review of the common neurodegenerative disorders: Current therapeutic approaches and the potential role of nanotherapeutics.Int. J. Mol. Sci.2022233185110.3390/ijms23031851 35163773
     [Google Scholar]
  2. JankovskaN. RusinaR. BruzovaM. ParobkovaE. OlejarT. MatejR. Human prion disorders: Review of the current literature and a twenty-year experience of the national surveillance center in the czech republic.Diagnostics20211110182110.3390/diagnostics11101821 34679519
     [Google Scholar]
  3. GeschwindM.D. Prion diseases.Continuum20152161612163810.1212/CON.0000000000000251
     [Google Scholar]
  4. SatohK. CSF biomarkers for prion diseases.Neurochem. Int.202215510530610.1016/j.neuint.2022.105306 35176437
     [Google Scholar]
  5. KranitzF. SimpsonD. Using non-pharmacological approaches for CJD patient and family support as provided by the CJD foundation and CJD insight.CNS Neurol. Disord. Drug Targets20098537237910.2174/187152709789542005 19702572
     [Google Scholar]
  6. SitammagariK.K. MasoodW. Creutzfeldt Jakob Disease.Treasure Island, FLStatPearls Publishing2024
     [Google Scholar]
  7. ChenC. DongX.P. Epidemiological characteristics of human prion diseases.Infect. Dis. Poverty2016514710.1186/s40249‑016‑0143‑8 27251305
     [Google Scholar]
  8. WeberD.J. RutalaW.A. Managing the risk of nosocomial transmission of prion diseases.Curr. Opin. Infect. Dis.200215442142510.1097/00001432‑200208000‑00011 12130940
     [Google Scholar]
  9. KennedyR.H. HoganR.N. BrownP. Eye banking and screening for Creutzfeldt-Jakob disease.Arch. Ophthalmol.2001119572172610.1001/archopht.119.5.721 11346399
     [Google Scholar]
  10. WeinsteinR.A. RutalaW.A. WeberD.J. Creutzfeldt-Jakob disease: Recommendations for disinfection and sterilization.Clin. Infect. Dis.20013291348135610.1086/319997 11303271
     [Google Scholar]
  11. MaY. MaJ. Immunotherapy against Prion Disease.Pathogens20209321610.3390/pathogens9030216 32183309
     [Google Scholar]
  12. MeadS. Khalili-ShiraziA. PotterC. Prion protein monoclonal antibody (PRN100) therapy for Creutzfeldt-Jakob disease: Evaluation of a first-in-human treatment programme.Lancet Neurol.202221434235410.1016/S1474‑4422(22)00082‑5 35305340
     [Google Scholar]
  13. LiuF. LüW. LiuL. New implications for prion diseases therapy and prophylaxis.Front. Mol. Neurosci.202417132470210.3389/fnmol.2024.1324702 38500676
     [Google Scholar]
  14. BamiaA. SinaneM. Naït-SaïdiR. Anti-prion drugs targeting the protein folding activity of the ribosome reduce PABPN1 aggregation.Neurotherapeutics20211821137115010.1007/s13311‑020‑00992‑6 33533011
     [Google Scholar]
  15. AyeniE.A. AldossaryA.M. AyejotoD.A. Neurodegenerative diseases: Implications of environmental and climatic influences on neurotransmitters and neuronal hormones activities.Int. J. Environ. Res. Public Health202219191249510.3390/ijerph191912495 36231792
     [Google Scholar]
  16. GallardoM. DelgadoF. Animal prion diseases: A review of intraspecies transmission.Open Vet. J.202111470772310.5455/OVJ.2021.v11.i4.23 35070868
     [Google Scholar]
  17. BaiardiS. MammanaA. CapellariS. ParchiP. Human prion disease: Molecular pathogenesis, and possible therapeutic targets and strategies.Expert Opin. Ther. Targets202327121271128410.1080/14728222.2023.2199923 37334903
     [Google Scholar]
  18. AguzziA. HeppnerF.L. Pathogenesis of prion diseases: A progress report.Cell Death Differ.200071088990210.1038/sj.cdd.4400737 11279534
     [Google Scholar]
  19. BenarrochE. What are the roles of cellular prion protein in normal and pathologic conditions?Neurology2024102720927210.1212/WNL.0000000000209272 38484222
     [Google Scholar]
  20. ApplebyB.S. ShettyS. ElkasabyM. Genetic aspects of human prion diseases.Front. Neurol.202213100305610.3389/fneur.2022.1003056 36277922
     [Google Scholar]
  21. LadoganaA. KovacsG.G. Genetic Creutzfeldt–Jakob disease.Handb. Clin. Neurol.201815321924210.1016/B978‑0‑444‑63945‑5.00013‑1 29887139
     [Google Scholar]
  22. GhettiB. PiccardoP. ZanussoG. Dominantly inherited prion protein cerebral amyloidoses – a modern view of Gerstmann–Sträussler-Scheinker.Handb. Clin. Neurol.201815324326910.1016/B978‑0‑444‑63945‑5.00014‑3 29887140
     [Google Scholar]
  23. CraccoL. ApplebyB.S. GambettiP. Fatal familial insomnia and sporadic fatal insomnia.Handb. Clin. Neurol.201815327129910.1016/B978‑0‑444‑63945‑5.00015‑5 29887141
     [Google Scholar]
  24. BagyinszkyE. GiauV.V. YounY.C. A AnS.S. KimS. Characterization of mutations in PRNP (prion) gene and their possible roles in neurodegenerative diseases.Neuropsychiatr. Dis. Treat.2018142067208510.2147/NDT.S165445 30147320
     [Google Scholar]
  25. RayiA. MurrN.I. Electroencephalogram.Treasure Island, FLStatPearls Publishing2024
     [Google Scholar]
  26. AltunaM. RuizI. ZelayaM.V. MendiorozM. Role of biomarkers for the diagnosis of prion diseases: A narrative review.Medicina202258447310.3390/medicina58040473 35454316
     [Google Scholar]
  27. WieserH. SchindlerK. ZumstegD. EEG in creutzfeldt–jakob disease.Clin. Neurophysiol.2006117593595110.1016/j.clinph.2005.12.007 16442343
     [Google Scholar]
  28. SaccoS. PaolettiM. StaffaroniA.M. Multimodal MRI staging for tracking progression and clinical-imaging correlation in sporadic Creutzfeldt-Jakob disease.Neuroimage Clin.20213010252310.1016/j.nicl.2020.102523 33636540
     [Google Scholar]
  29. AlsiaryR.A. AlghrablyM. SaoudiA. Using NMR spectroscopy to investigate the role played by copper in prion diseases.Neurol. Sci.20204192389240610.1007/s10072‑020‑04321‑9 32328835
     [Google Scholar]
  30. BiljanI. IlcG. PlavecJ. Understanding the Effect of Disease-Related Mutations on Human Prion Protein Structure: Insights From NMR Spectroscopy.Prog. Mol. Biol. Transl. Sci.20171508310310.1016/bs.pmbts.2017.06.006 28838676
     [Google Scholar]
  31. TelanoL.N. BakerS. Physiology, Cerebral Spinal Fluid.Treasure Island, FLStatPearls Publishing2024
     [Google Scholar]
  32. BergD. HolzmannC. RiessO. 14-3-3 proteins in the nervous system.Nat. Rev. Neurosci.20034975276210.1038/nrn1197 12951567
     [Google Scholar]
  33. HermannP. ApplebyB. BrandelJ.P. Biomarkers and diagnostic guidelines for sporadic Creutzfeldt-Jakob disease.Lancet Neurol.202120323524610.1016/S1474‑4422(20)30477‑4 33609480
     [Google Scholar]
  34. MuayqilT. GronsethG. CamicioliR. Evidence-based guideline: Diagnostic accuracy of CSF 14-3-3 protein in sporadic creutzfeldt-jakob disease.Neurology201279141499150610.1212/WNL.0b013e31826d5fc3 22993290
     [Google Scholar]
  35. WangY. MandelkowE. Tau in physiology and pathology.Nat. Rev. Neurosci.2016171223510.1038/nrn.2015.1 26631930
     [Google Scholar]
  36. ThompsonA.G.B. MeadS.H. Review: Fluid biomarkers in the human prion diseases.Mol. Cell. Neurosci.201997819210.1016/j.mcn.2018.12.003 30529227
     [Google Scholar]
  37. ZerrI. Villar-PiquéA. SchmitzV.E. Evaluation of human cerebrospinal fluid malate dehydrogenase 1 as a marker in genetic prion disease patients.Biomolecules201991280010.3390/biom9120800 31795176
     [Google Scholar]
  38. LiebermanP.L. SettipaneR.A. Azelastine nasal spray: A review of pharmacology and clinical efficacy in allergic and nonallergic rhinitis.Allergy Asthma Proc.200324295105 12776442
     [Google Scholar]
  39. DhaliwalJ.S. SpurlingB.C. MollaM. Duloxetine.Treasure Island, FLStatPearls Publishing2024
     [Google Scholar]
  40. SastreJ. Ebastine in the treatment of allergic rhinitis and urticaria: 30 years of clinical studies and real-world experience.J. Investig. Allergol. Clin. Immunol.202030315616810.18176/jiaci.0401 30977465
     [Google Scholar]
  41. Pubchem compound summary for CID 941361, flunarizine.2021Available from: https://pubchem.ncbi.nlm.nih.gov/compound/Flunarizine
  42. SahiN. NguyenR. PatelP. Loperamide.Treasure Island, FLStatPearls Publishing2024
     [Google Scholar]
  43. Pubchem compound summary for CID 4167, metixene.2021Available from: https://pubchem.ncbi.nlm.nih.gov/compound/Metixene
  44. MailleJ.M. HannaS.S. ShahD.N. Addition of clobazam successfully treating drug resistant seizures in Heidenhain variant Creutzfeldt Jakob disease: A case report.Epilepsy Behav. Rep.20232110058510.1016/j.ebr.2023.100585 36698381
     [Google Scholar]
  45. PriceJ.R. KheirbekR.E. Addressing the unmet needs of patients with rapidly progressive neurological disease: A case report of palliative care in creutzfeldt-jakob disease (CJD).Cureus20241625522810.7759/cureus.55228 38558630
     [Google Scholar]
  46. Tabaee DamavandiP. DoveM.T. PickersgillR.W. A review of drug therapy for sporadic fatal insomnia.Prion201711529329910.1080/19336896.2017.1368937 28976233
     [Google Scholar]
  47. ApplebyB.S. YobsD.R. Symptomatic treatment, care, and support of CJD patients.Handb. Clin. Neurol.201815339940810.1016/B978‑0‑444‑63945‑5.00021‑0 29887147
     [Google Scholar]
  48. MinikelE.V. ZhaoH.T. LeJ. Prion protein lowering is a disease-modifying therapy across prion disease stages, strains and endpoints.Nucleic Acids Res.20204819106151063110.1093/nar/gkaa616 32776089
     [Google Scholar]
  49. WagnerJ. RyazanovS. LeonovA. Anle138b: A novel oligomer modulator for disease-modifying therapy of neurodegenerative diseases such as prion and Parkinson’s disease.Acta Neuropathol.2013125679581310.1007/s00401‑013‑1114‑9 23604588
     [Google Scholar]
  50. ShimK.H. SharmaN. AnS.S.A. Prion therapeutics: Lessons from the past.Prion202216126529410.1080/19336896.2022.2153551 36515657
     [Google Scholar]
  51. AbdelazizD.H. AbdulrahmanB.A. GilchS. SchatzlH.M. Autophagy pathways in the treatment of prion diseases.Curr. Opin. Pharmacol.201944465210.1016/j.coph.2019.04.013 31096117
     [Google Scholar]
  52. NapperS. SchatzlH.M. Vaccines for prion diseases: A realistic goal?Cell Tissue Res.2023392136739210.1007/s00441‑023‑03749‑7 36764940
     [Google Scholar]
  53. VargesD. MantheyH. HeinemannU. Doxycycline in early CJD: A double-blinded randomised phase II and observational study.J. Neurol. Neurosurg. Psychiatry201788211912510.1136/jnnp‑2016‑313541 27807198
     [Google Scholar]
  54. McNivenK. NihatA. MokT.H. Enteral feeding is associated with longer survival in the advanced stages of prion disease.Brain Commun.201911fcz01210.1093/braincomms/fcz012 32954259
     [Google Scholar]
  55. GoldmanJ.S. VallabhS.M. Genetic counseling for prion disease: Updates and best practices.Genet. Med.202224101993200310.1016/j.gim.2022.06.003 35819418
     [Google Scholar]
  56. TsuboiY. Doh-uraK. YamadaT. Continuous intraventricular infusion of pentosan polysulfate: Clinical trial against prion diseases.Neuropathology200929563263610.1111/j.1440‑1789.2009.01058.x 19788637
     [Google Scholar]
  57. TakatsukiH. ImamuraM. MoriT. AtarashiR. Pentosan polysulfate induces low-level persistent prion infection keeping measurable seeding activity without PrP-res detection in Fukuoka-1 infected cell cultures.Sci. Rep.2022121792310.1038/s41598‑022‑12049‑z 35562591
     [Google Scholar]
  58. MeddM.M. CaoQ. Perspectives on CRISPR genome editing to prevent prion diseases in high-risk individuals.Biomedicines2024128172510.3390/biomedicines12081725 39200190
     [Google Scholar]
  59. DuZ. ValtierraS. CardonaL.R. DunneS.F. LuanC.H. LiL. Identifying anti-prion chemical compounds using a newly established yeast high-throughput screening system.Cell Chem. Biol.2019261216641680.e410.1016/j.chembiol.2019.10.004 31668517
     [Google Scholar]
  60. McDonnellG. DehenC. PerrinA. Cleaning, disinfection and sterilization of surface prion contamination.J. Hosp. Infect.201385426827310.1016/j.jhin.2013.08.003 24074640
     [Google Scholar]
  61. Bovine spongiform encephalopathy (BSE).2024Available from: https://www.cdc.gov/mad-cow/php/animal-health/index.html
  62. Addressing foodborne threats to health: Policies, practices, and global coordination: Workshop summary.2006Available from: https://www.ncbi.nlm.nih.gov/books/NBK57084/
  63. All about BSE (mad cow disease).2020Available from: https://www.fda.gov/animal-veterinary/animal-health-literacy/all-about-bse-mad-cow-disease
  64. KufelJ. Bargieł-ŁączekK. KocotS. What is machine learning, artificial neural networks and deep learning?—examples of practical applications in medicine.Diagnostics20231315258210.3390/diagnostics13152582 37568945
     [Google Scholar]
  65. LepakshiV.A. Machine learning and deep learning based AI tools for development of diagnostic tools. Computational Approaches for Novel Therapeutic and Diagnostic Designing to Mitigate SARS-CoV-2 Infection. PariharA. KhanR. KumarA. United StatesAcademic Press202239942010.1016/B978‑0‑323‑91172‑6.00011‑X
     [Google Scholar]
  66. SalviM. MolinariF. CiccarelliM. TestiR. TaraglioS. ImperialeD. Quantitative analysis of prion disease using an AI-powered digital pathology framework.Sci. Rep.20231311775910.1038/s41598‑023‑44782‑4 37853094
     [Google Scholar]
  67. RajagopalB.G. ArockM. Application of machine learning techniques for study of drug interactions using clinical parameters for creutzfeldt-jakob disease.2020 IEEE-EMBS Conference on Biomedical Engineering and Sciences (IECBES) 2021, pp. 415-42010.1109/IECBES48179.2021.9398847
     [Google Scholar]
  68. WatsonN. KurudzhuH. GreenA. SummersD. SmithC. PalS. Application of telehealth for comprehensive Creutzfeldt-Jakob disease surveillance in the United Kingdom.J. Neurol. Sci.202142011722110.1016/j.jns.2020.117221 33223148
     [Google Scholar]
  69. GeissenM. LeidelF. EidenM. From high-throughput cell culture screening to mouse model: Identification of new inhibitor classes against prion disease.ChemMedChem20116101928193710.1002/cmdc.201100119 21755599
     [Google Scholar]
  70. IshibashiD. IshikawaT. MizutaS. Novel compounds identified by structure-based prion disease drug discovery using in silico screening delay the progression of an illness in prion-infected mice.Neurotherapeutics20201741836184910.1007/s13311‑020‑00903‑9 32767031
     [Google Scholar]
  71. IshibashiD. NakagakiT. IshikawaT. Structure-based drug discovery for prion disease using a novel binding simulation.EBioMedicine2016923824910.1016/j.ebiom.2016.06.010 27333028
     [Google Scholar]
  72. AliT. HannaouiS. NemaniS. Oral administration of repurposed drug targeting Cyp46A1 increases survival times of prion infected mice.Acta Neuropathol. Commun.2021915810.1186/s40478‑021‑01162‑1 33795005
     [Google Scholar]
  73. JiangD. NanH. ChenZ. ZouW.Q. WuL. Genetic insights into drug targets for sporadic Creutzfeldt-Jakob disease: Integrative multi-omics analysis.Neurobiol. Dis.202419910659910.1016/j.nbd.2024.106599 38996988
     [Google Scholar]
  74. VanniS. Omics of prion diseases.Prog. Mol. Biol. Transl. Sci.201715040943110.1016/bs.pmbts.2017.05.004 28838672
     [Google Scholar]
  75. CaseyC. SleatorR.D. Prions: Structure, function, evolution, and disease.Arch. Microbiol.20252071110.1007/s00203‑024‑04200‑3 39572454
     [Google Scholar]
  76. CanasL.S. SudreC.H. De VitaE. Prion disease diagnosis using subject-specific imaging biomarkers within a multi-kernel Gaussian process.Neuroimage Clin.20192410205110.1016/j.nicl.2019.102051 31734530
     [Google Scholar]
  77. AbdallahS. SharifaM. I Kh AlmadhounM.K. The impact of artificial intelligence on optimizing diagnosis and treatment plans for rare genetic disorders.Cureus202315104686010.7759/cureus.46860 37954711
     [Google Scholar]
  78. RossiM. BaiardiS. ParchiP. Understanding prion strains: Evidence from studies of the disease forms affecting humans.Viruses201911430910.3390/v11040309 30934971
     [Google Scholar]
  79. KurtT.D. SigurdsonC.J. Cross-species transmission of CWD prions.Prion2016101839110.1080/19336896.2015.1118603 26809254
     [Google Scholar]
  80. EidS. LeeS. VerkuylC.E. The importance of prion research.Biochem. Cell Biol.2024102644847110.1139/bcb‑2024‑0018 38996387
     [Google Scholar]
  81. GambettiP. KongQ. ZouW. ParchiP. ChenS.G. Sporadic and familial CJD: Classification and characterisation.Br. Med. Bull.200366121323910.1093/bmb/66.1.213 14522861
     [Google Scholar]
  82. SamekW. WiegandT. MüllerK. Explainable artificial intelligence: Understanding, visualizing and interpreting deep learning models.Available from: https://arxiv.org/abs/1708.08296 2017
  83. TeruyaK. Doh-uraK. Insights from therapeutic studies for prp prion disease.Cold Spring Harb. Perspect. Med.201773a02443010.1101/cshperspect.a024430 27836910
     [Google Scholar]
  84. CollinsS.D. Discontinued drugs in 2006: Central and peripheral nervous system drugs.Expert Opin. Investig. Drugs200716111743175110.1517/13543784.16.11.1743 17970635
     [Google Scholar]
  85. ZerrI. PoserS. Clinical diagnosis and differential diagnosis of CJD and vCJD.Acta Pathol Microbiol Scand Suppl20021101889810.1034/j.1600‑0463.2002.100111.x 12064260
     [Google Scholar]
  86. BaldwinK.J. CorrellC.M. Prion disease.Semin. Neurol.201939442843910.1055/s‑0039‑1687841 31533183
     [Google Scholar]
  87. IronsideJ.W. RitchieD.L. HeadM.W. Prion diseases.Handb. Clin. Neurol.201814539340310.1016/B978‑0‑12‑802395‑2.00028‑6 28987186
     [Google Scholar]
  88. Piñar-MoralesR. Barrero-HernándezF. Aliaga-MartínezL. Human prion diseases: An overview.Medic. Clin.20231601255456010.1016/j.medcli.2023.03.001
     [Google Scholar]
  89. OrrúC.D. GrovemanB.R. RaymondL.D. Bank vole prion protein as an apparently universal substrate for RT-quic-based detection and discrimination of prion strains.PLoS Pathog.2015116100498310.1371/journal.ppat.1004983 26086786
     [Google Scholar]
  90. MeyneF. GloecknerS.F. CiesielczykB. Total prion protein levels in the cerebrospinal fluid are reduced in patients with various neurological disorders.J. Alzheimers Dis.200917486387310.3233/JAD‑2009‑1110 19542614
     [Google Scholar]
  91. SteinhoffB.J. ZerrI. GlattingM. Schulz-SchaefferW. PoserS. KretzschmarH.A. Diagnostic value of periodic complexes in Creutzfeldt-Jakob disease.Ann. Neurol.200456570270810.1002/ana.20261 15449324
     [Google Scholar]
  92. ZerrI. BodemerM. GefellerO. Detection of 14‐3‐3 protein in the cerebrospinal fluid supports the diagnosis of Creutzfeldt‐Jakob disease.Ann. Neurol.1998431324010.1002/ana.410430109 9450766
     [Google Scholar]
  93. KnightR. BrazierM. CollinsS.J. Human prion diseases: Cause, clinical and diagnostic aspects.Contrib. Microbiol.200411729710.1159/000077051 15077404
     [Google Scholar]
  94. HaïkS. MarconG. MalletA. Doxycycline in Creutzfeldt-Jakob disease: A phase 2, randomised, double-blind, placebo-controlled trial.Lancet Neurol.201413215015810.1016/S1474‑4422(13)70307‑7 24411709
     [Google Scholar]
  95. WhiteA.R. EneverP. TayebiM. Monoclonal antibodies inhibit prion replication and delay the development of prion disease.Nature20034226927808310.1038/nature01457 12621436
     [Google Scholar]
  96. DaudeN. WestawayD. Shadoo/PrP (Sprn0/0/Prnp0/0) double knockout mice.Prion20126542042410.4161/pri.21867 22929230
     [Google Scholar]
  97. PuotiG. BizziA. ForloniG. SafarJ.G. TagliaviniF. GambettiP. Sporadic human prion diseases: Molecular insights and diagnosis.Lancet Neurol.201211761862810.1016/S1474‑4422(12)70063‑7 22710755
     [Google Scholar]
  98. BradfordB.M. PiccardoP. IronsideJ.W. MabbottN.A. Human prion diseases and the risk of their transmission during anatomical dissection.Clin. Anat.201427682183210.1002/ca.22403 24740900
     [Google Scholar]
  99. OuteiroT.F. HöglingerG. LangA.E. VieiraT.C.R.G. Protein misfolding: Understanding biology to classify and treat synucleinopathies.J. Neural Transm.20251610.1007/s00702‑025‑02889‑0 39932548
     [Google Scholar]
  100. ZhaoY. JaberV.R. LukiwW.J. SARS-CoV-2, long COVID, prion disease and neurodegeneration.Front. Neurosci.202216100277010.3389/fnins.2022.1002770 36238082
     [Google Scholar]
/content/journals/cnsnddt/10.2174/0118715273381241250620114740
Loading
Insights into the Diagnosis, Treatment, and Management of Prion Diseases
CNS Neurol. Disord. Drug Targets 25, 25 (2026); https://doi.org/10.2174/0118715273381241250620114740
/content/journals/cnsnddt/10.2174/0118715273381241250620114740
/content/journals/cnsnddt/10.2174/0118715273381241250620114740
Loading

Data & Media loading...


  • Article Type:     Review Article
Keyword(s): Artificial intelligence; gene therapy; management; neurodegenerative disorder; pathogenesis; prion disease

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test